PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

导出 OA

翻译打印收藏纠错

作者： Roman M,Chabanon ^[1] ; Gareth,Muirhead ^[2] ; Dragomir B,Krastev ^[3] ; Julien,Adam ^[4] ; Daphné,Morel ^[3] ; Marlène,Garrido ^[3] ; Andrew,Lamb ^[4] ; Clémence,Hénon ^[2] ; Nicolas,Dorvault ^[1] ; Mathieu,Rouanne ^[2] ; Rebecca,Marlow ^[2] ; Ilirjana,Bajrami ^[5] ; Marta Llorca,Cardeñosa ^[1] ; Asha,Konde ^[2] ; Benjamin,Besse ^[2] ; Alan,Ashworth ^[1] ; Stephen J,Pettitt ^[6] ; Syed,Haider ^[7] ; Aurélien,Marabelle ^[3] ; Andrew Nj,Tutt ^[4] ; Jean-Charles,Soria ^[3] ; Christopher J,Lord ^[4] ; Sophie,Postel-Vinay ^[8]

作者单位： Université Paris Saclay, Université Paris-Sud, Faculté de médicine, Le Kremlin Bicêtre, Paris, France. ^[1] ATIP-Avenir group, Inserm U981, Gustave Roussy, Villejuif, France. ^[2] The Breast Cancer Now Toby Robins Breast Cancer Research Centre and. ^[3] CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom. ^[4] Sage Bionetworks, Seattle, Washington, USA. ^[5] Inserm U1015, Gustave Roussy, Villejuif, France. ^[6] The Breast Cancer Now Research Unit, King's College London, London, United Kingdom. ^[7] Biomedical Research Institute INCLIVA, Hospital Clinico Universitario Valencia, University of Valencia, Valencia, Spain. ^[8] Department of Medical Oncology, Gustave Roussy, Villejuif, France. ^[9] UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. ^[10] Département d'Innovations Thérapeutiques et Essais Précoces (DITEP), Gustave Roussy, Villejuif, France. ^[11]

关键词 Cellular immune response DNA repair Lung cancer Oncology